Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus ZUPLENZ.
PROMETHAZINE VC W/ CODEINE vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic